Open an Account
search icon
1
NOTIFICATIONS
Best Algo trading app in India
Bigul

GENESYS INTERNATIONAL CORPORATION LTD. - 506109 - Announcement under Regulation 30 (LODR)-Allotment

 The Board of Directors of the Company, at their meeting held on August 16, 2022, have inter alia considered and approved the following: The holder of Compulsorily Convertible Debentures (CCDs) namely Florintree Innovation LLP (Non-Promoter) has exercised its right of conversion of 15,00,000 CCDs into Equity Shares. Accordingly, in accordance with the Special Resolution passed by Shareholders at their Extra-ordinary General Meeting held on 31st July, 2021, the Board of Directors in its meeting held on August 16, 2022, have allotted pursuant to aforesaid conversion, 15,00,000 Equity Shares of Rs. 5/- each fully paid up at a securities premium of Rs 117/- per share. (i.e. in the ratio of 1 Equity Share for every 1 CCDs held). The meeting of Board commenced at 7.30 p.m. and concluded at 8.30 p.m. Kindly take the above information on your record.
17-08-2022
Bigul

GENESYS INTERNATIONAL CORPORATION LTD. - 506109 - Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

 the Board of Directors of the Company, at their meeting held on August 16, 2022, have inter alia considered and approved the following: i. Re-appointment of Mr. Sajid Malik as Managing Director designated as 'Chairman & Managing Director' of the Company for a period of 3 years w.e.f. from September 01, 2022, subject to approval of shareholders. ii. Re-appointment of Mrs. Saroja Malik as Whole-time Director of the Company for a period of 3 years w.e.f. from August 17, 2022, subject to approval of shareholders. iii. The holder of Compulsorily Convertible Debentures (CCDs) namely Florintree Innovation LLP has exercised its right of conversion of 15,00,000 CCDs into Equity Shares. The Board of Directors in its meeting held on August 16, 2022, have allotted pursuant to aforesaid conversion, 15,00,000 Equity Shares of Rs. 5/- each fully paid up at a securities premium of Rs 117/- per share. (i.e. in the ratio of 1 Equity Share for every 1 CCDs held).
17-08-2022
Bigul

GENESYS INTERNATIONAL CORPORATION LTD. - 506109 - Announcement under Regulation 30 (LODR)-Newspaper Publication

 We are enclosing herewith the copy of Standalone and Consolidated unaudited financial results of the Company for the quarter ended June 30, 2022 as published in the Newspaper - The Free Press Journal (English) and Navshakti (Marathi) on Sunday, August 14, 2022. Request you to take the same on records.
16-08-2022

Genesys Int Standalone June 2022 Net Sales at Rs 42.62 crore, up 211.73% Y-o-Y

 NULL
16-08-2022
Bigul

GENESYS INTERNATIONAL CORPORATION LTD. - 506109 - Statement Of Deviation Or Variation Or Utilization Of Funds Raised Under Preferential Issue - Regulation 32(1) Of SEBI (LODR) Regulations, 2015 For The Quarter Ended June 30, 2022

 In compliance with the Regulation 32(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 please find attached the Statement of Deviation or Variation or Utilization of funds raised through Preferential Issue by the Company for the quarter and ended June 30, 2022 as reviewed by the Audit Committee. You are requested to take the above on your records.
12-08-2022
Bigul

GENESYS INTERNATIONAL CORPORATION LTD. - 506109 - Announcement under Regulation 30 (LODR)-Resignation of Director

 the Board of Directors of the Company, at their meeting held today i.e August 12, 2022 has inter alia considered and approved the following: Resignation of Mr. Hemant Majethia (DIN: 00400473), Independent Director of the Company w.e.f closure of business hours of August 12, 2022 on account of other professional commitments. We further confirm that there is no other material reason for his resignation other than as stated above The meeting of Board commenced at 4.30 p.m. and concluded at 6.00 p.m.
12-08-2022
Bigul

GENESYS INTERNATIONAL CORPORATION LTD. - 506109 - Announcement under Regulation 30 (LODR)-Change in Directorate

 The Board of Directors of the Company, at their meeting held today i.e August 12, 2022 has inter alia considered and approved the following: Appointment of Ms. Bharti Sinha (DIN: 07985813) as an Additional Director- Non-Executive Independent Director of the Company w.e.f August 12, 2022. Resignation of Mr. Hemant Majethia (DIN: 00400473), Independent Director of the Company w.e.f closure of business hours of August 12, 2022 on account of other professional commitments. We further confirm that there is no other material reason for his resignation other than as stated above. The meeting of Board commenced at 4.30 p.m. and concluded at 6.00 p.m.
12-08-2022
Bigul

GENESYS INTERNATIONAL CORPORATION LTD. - 506109 - Board Meeting Outcome for Outcome Of Board Meeting Held On August 12, 2022

 The Board of Directors of the Company, at their meeting held today i.e August 12, 2022 has inter alia considered and approved the following: Un-audited Financial Results (Standalone and Consolidated) for the quarter ended June 30, 2022. Copies of the following is enclosed as Annexure- I Appointment of Ms. Bharti Sinha (DIN: 07985813) as an Additional Director- Non-Executive Independent Director of the Company w.e.f August 12, 2022. Resignation of Mr. Hemant Majethia (DIN: 00400473), Independent Director of the Company w.e.f closure of business hours of August 12, 2022 on account of other professional commitments. We further confirm that there is no other material reason for his resignation other than as stated above.
12-08-2022
Bigul

GENESYS INTERNATIONAL CORPORATION LTD. - 506109 - Results- Financial Results For Quarter Ended 30Th June 2022

 In compliance with the provisions of Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company, at their meeting held today i.e August 12, 2022 has inter alia considered and approved the following: i. Un-audited Financial Results (Standalone and Consolidated) for the quarter ended June 30, 2022. Copies of the following is enclosed as Annexure- I Un-audited Financial Results (Standalone and Consolidated) for the quarter ended June 30, 2022. Limited Review Report of the Statutory Auditors on aforesaid results The meeting of Board commenced at 4.30 p.m. and concluded at 6.00 p.m.
12-08-2022
Bigul

GENESYS INTERNATIONAL CORPORATION LTD. - 506109 - Board Meeting Intimation for Intimation Of Board Meeting To Approve The Un-Audited Financial Results For The Quarter Ended June 30, 2022.

 GENESYS INTERNATIONAL CORPORATION LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2022 ,inter alia, to consider and approve Pursuant to the provisions under Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and other applicable provisions, rules and regulations, if any, this is to inform you that a meeting of the Board of Directors of the Company will be held on Friday, August 12, 2022, to inter alia consider and approve the un-audited financial results (standalone and consolidated) for the quarter ended June 30, 2022. Kindly take the above on your records.
06-08-2022
Next Page
Close

Let's Open Free Demat Account